Abstract
Mixed lineage kinase domain-like protein (MLKL) is a pseudokinase featured by a protein kinase-like domain without catalytic activity. MLKL was originally discovered to be phosphorylated by receptor-interacting protein kinase 1/3, typically increasing plasma membrane permeabilization and disrupting membrane integrity, ultimately executing necroptosis. Recent evidence uncovers the association of MLKL with diverse cellular organelles, including the mitochondrion, lysosome, endosome, endoplasmic reticulum, and nucleus. This review focuses on the regulatory functions, mechanisms, and targets of MLKL in organelles beyond its role in necroptosis and summarizes its medical significance in multiple diseases. We analyze current progress in MLKL-related drug development, from natural products and small molecules to proteolysis-targeting chimeras (PROTACs), aiming to propel MLKL as a valid drug target.
Introduction: Beyond the 'Executioner' Dogma
For years, Mixed lineage kinase domain-like protein (MLKL) was viewed through a narrow lens: it was the 'executioner' of necroptosis. Upon phosphorylation by receptor-interacting protein kinase 3 (RIPK3), MLKL oligomerizes and translocates to the plasma membrane, punching holes that disrupt membrane integrity and trigger cell death. However, recent research has challenged this singular focus. MLKL is frequently found associated with internal organelles—such as mitochondria, the endoplasmic reticulum (ER), and lysosomes—well before the onset of cell death. This review synthesizes evidence showing that MLKL acts as a sophisticated regulatory machinery for organelle dynamics, influencing pathologies ranging from neurodegeneration to cancer.
Structural Basis and the Pseudokinase Switch
MLKL is a pseudokinase, meaning it possesses a kinase-like domain (PsKD) but lacks catalytic activity. Instead, the PsKD functions as a conformational switch. The protein consists of three main components: the N-terminal 'killer' four-helix bundle domain (4HBD), the C-terminal PsKD, and a 'brace' linker. Phosphorylation by RIPK3 'unleashes' the 4HBD, allowing it to interact with various cellular membranes.
A critical consideration for translation is species divergence. Mouse and human MLKL are structurally distinct; mouse MLKL relies on a specific K219:Q343 interaction to maintain its 'off' state, whereas human MLKL utilizes a 'closed' conformation. This structural difference explains why many inhibitors successful in murine models fail in human clinical trials.
Mitochondrial and ER Homeostasis
MLKL plays a pivotal role in regulating mitochondrial shape and function. Rather than simply destroying the organelle, MLKL can recruit PGAM5 to the mitochondrial membrane, which in turn activates Drp1 to trigger mitochondrial fission. This regulatory event can occur independently of the final necroptotic signal. Furthermore, MLKL functions as a cation channel in the ER and mitochondrial membranes, specifically balancing $Mg^{2+}$ levels. This ion flux is vital for stabilizing organelle transportation and limiting the production of reactive oxygen species (ROS).
As shown in Figure 1, MLKL also modulates mitophagy. By reducing LC3B and arresting p62, MLKL can inhibit PINK1-mediated mitophagy, further impacting mitochondrial homeostasis and contributing to oxidative stress or ER dysfunction.
Lysosomal Regulation and Endosomal Trafficking
MLKL’s influence extends to the cell's 'garbage disposal' and recycling systems. In lysosomes, MLKL can trigger lysosomal membrane permeabilization (LMP) and the release of cathepsins, or influence lysosome aggregation and fusion. It also interacts with the PI3K/AKT/mTOR signaling axis to modulate autophagy.
In the endosomal pathway (Figure 2), MLKL facilitates the transport of receptors and ligands to multivesicular bodies for degradation. This role in endosomal trafficking is particularly significant in certain leukemias, where MLKL acts as a tumor suppressor by regulating the degradation of growth factor receptors like EGFR.
Targeted Therapeutics: From Natural Products to PROTACs
The emerging understanding of MLKL’s diverse roles has spurred the development of novel therapeutics:
- Natural Products: Compounds like Baicalin and Luteolin offer 'gentle' modulation by inhibiting MLKL oligomerization or phosphorylation.
- Small-Molecule Inhibitors: Necrosulfonamide (NSA) remains a primary research tool, targeting the C86 residue to block membrane translocation. Clinical repurposing of existing drugs, such as the antihypertensive Azilsartan, has also shown indirect MLKL inhibition.
- PROTACs: Next-generation proteolysis-targeting chimeras (PROTACs) represent a significant leap forward. Instead of merely blocking activity, PROTACs recruit the cellular proteasome to degrade MLKL entirely, offering higher specificity and more durable therapeutic effects.
Conclusion and Future Perspectives
Transitioning MLKL from a cell death marker to a therapeutic target requires overcoming several hurdles. Future work must address organelle specificity—targeting MLKL in diseased mitochondria without disrupting its beneficial roles in endosomal trafficking. Additionally, the development of 'humanized' models is essential to bridge the gap created by species-specific structural differences. By refining our ability to modulate MLKL, we may unlock new treatments for a vast array of inflammatory and degenerative diseases.
Summary updated